Gastrointestinal Pharmaceuticals: Technologies And Global Markets
October 22, 2009
Wellesley, Mass. – According to a new technical market research report, GASTROINTESTINAL PHARMACEUTICALS: TECHNOLOGIES AND GLOBAL MARKETS (PHM046B) from BCC Research (www.bccresearch.com), the global market for gastrointestinal drugs will be worth an estimated $31 billion in 2009. That is expected to increase to more than $32 billion in 2014, for a 5-year compound annual growth rate (CAGR) of 0.7%.
The largest segment of the market, prescription gastrointestinal drugs, is expected to be worth more than $26 billion in 2009, and to increase to nearly $27 billion in 2014, for a 5-year CAGR of 0.5%.
The other segment of the market, over-the-counter gastrointestinal drugs, is estimated to be worth $4.8 billion in 2009. By 2014, that is expected to grow at a CAGR of 1.7% to reach $5.2 billion.
The gastrointestinal drug market is rapidly growing due to recent advancements in pharmaceutical products, advancements in drug delivery of medications and accurate diagnosis. Emphasis has been placed on early detection and treatment of disorders.
SUMMARY FIGURE
GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014
($ MILLIONS)
To Contact us, click here 
Source: BCC Research
This report is designed to be a comprehensive business tool to provide an in-depth look at gastrointestinal disorders. It provides an overview of the gastrointestinal system; gives a brief explanation of disorders of the gastrointestinal system; cites risk factors, where applicable; cites incidence and mortality; presents current pharmaceutical treatments, market size and market participants in both prescription and over-the-counter arenas; and presents potential treatments in research and development, potential market size and market participants.
Aside from the two general segments, prescription and over-the-counter gastrointestinal pharmaceuticals, the market is further broken down into the drugs to treat specific disorders within the gastrointestinal system including:
- Gastrointestinal tract disorders
- Gastrointestinal tract wall disorders
- Gastrointestinal motility disorders
- Gastrointestinal malabsorption disorders
- Gastrointestinal cancers.
Each subsegment is addressed in detail, describing disorders and the diseases, identifying current and potential products on the market, and competitors involved in the market.
Gastrointestinal Pharmaceuticals: Technologies and Markets( PHM046B )
Publish Date: Sep 2009
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
Gastrointestinal Pharmaceuticals: Technologies and Markets
Customize This Report More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand